Synplogen Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 41

Employees

  • Latest Deal Type
  • Series F

  • Latest Deal Amount
  • $1.23M

  • Investors
  • 23

Synplogen General Information

Description

Provider of DNA synthesis and biofoundry services intended to support the development of gene therapy products. The company utilizes proprietary gene assembly methods and integrated research facilities to provide custom DNA synthesis, library construction, and viral vector development, enabling pharmaceutical and biotechnology organizations to accelerate clinical trials and commercialize genetic medicines.

Contact Information

Website
www.synplogen.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Creative Lab Kobe 4th Floor
  • 6-3-7 Minatojima-Minamimachi, Chuo-ku
  • Kobe, 650-0047
  • Japan
Primary Industry
Other Pharmaceuticals and Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Creative Lab Kobe 4th Floor
  • 6-3-7 Minatojima-Minamimachi, Chuo-ku
  • Kobe, 650-0047
  • Japan

Synplogen Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Synplogen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series F) 01-Aug-2026 $1.23M Completed Generating Revenue
10. Accelerator/Incubator 09-Jul-2026 Completed Generating Revenue
9. Later Stage VC (Series E) 01-Jun-2026 Completed Generating Revenue
8. Accelerator/Incubator 11-Mar-2026 Completed Generating Revenue
7. Later Stage VC (Series D) 27-Jan-2025 Completed Generating Revenue
6. Later Stage VC (Series C) 02-Mar-2023 Completed Generating Revenue
5. Early Stage VC (Series B) 28-Dec-2021 Completed Generating Revenue
4. Accelerator/Incubator 01-Oct-2020 Completed Generating Revenue
3. Early Stage VC (Series A) 28-May-2019 $10M $10.9M Completed Generating Revenue
2. Seed Round 09-Oct-2018 $886K $886K Completed Generating Revenue
To view Synplogen’s complete valuation and funding history, request access »

Synplogen Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
D Share
C Shares
B Shares 153 $27887.95 $27887.95 1x $27887.95 9.21%
A Shares 396 $17687.92 $17687.92 1x $17687.92 23.83%
To view Synplogen’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Synplogen Patents

  • 72

    Total Documents Applications and Grants

  • Total Patents Families

  • 18

    Granted

  • 44

    Pending

  • Expiring in next 12 mo

Synplogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026048921-A1 Random mutation library Pending 29-Aug-2024
WO-2026018850-A1 High-performance nucleic acid construct and design method for same Pending 16-Jul-2024
WO-2025263459-A1 Biopharmaceutical composition Pending 17-Jun-2024
WO-2025041806-A1 Ribonucleic acid production technology Inactive 22-Aug-2023
EP-4726027-A1 Production of substance by strain Pending 09-Jun-2023 C12N15/75
To view Synplogen’s complete patent history, request access »

Synplogen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Synplogen Investors (23)

Investor Name Investor Type Holding Investor Since Participating Rounds
Japan Finance Government
Tokyo Star Bank Corporation
SusHi Tech Tokyo Accelerator/Incubator
Kansai Felt Fabric Corporation Minority
Meiji Holdings Holding Company Minority
You’re viewing 5 of 23 investors. Get the full list »

Synplogen Investments (1)

Synplogen’s most recent deal was a Seed Round with GenomeMiner AI for . The deal was made on 24-Jul-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
GenomeMiner AI 24-Jul-2019 Seed Round Biotechnology
To view Synplogen’s complete investments history, request access »

Ready to get started?

Request a free trial

Synplogen FAQs

  • When was Synplogen founded?

    Synplogen was founded in 2017.

  • Where is Synplogen headquartered?

    Synplogen is headquartered in Kobe, Japan.

  • What is the size of Synplogen?

    Synplogen has 41 total employees.

  • What industry is Synplogen in?

    Synplogen’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Synplogen a private or public company?

    Synplogen is a Private company.

  • What is Synplogen’s current revenue?

    The current revenue for Synplogen is .

  • How much funding has Synplogen raised over time?

    Synplogen has raised $36.2M.

  • Who are Synplogen’s investors?

    Japan Finance, Tokyo Star Bank, SusHi Tech Tokyo, Kansai Felt Fabric, and Meiji Holdings are 5 of 23 investors who have invested in Synplogen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process